The Romanian Competition Authority fines EUR 22.6 M distributors and manufacturer for sharing insulin portfolio (Eli Lilly / A&A Medical / Mediplus Exim / Relad Pharma)

The Romanian Competition Council (the “Council”) continued in 2008 the series of decisions dedicated to the malfunctioning of the Romanian pharmaceutical market, by sanctioning through its decision 15/2008 (i) the insulin producer Eli Lilly Export SA and three of its distributors, A&A Medical SRL (“A&A”), Relad Pharma SRL (“Relad”) and Mediplus Exim SRL (“Mediplus”) for the breach of article 5 (1) c) of the Competition Law n° 21/1996 (the “Competition Law”) and (ii) the Ministry of Public Health for the breach of article 9 of the Competition Law. The very ample and detailed decision (100 pages) carefully reasons various matters such as: relevant market, distinction between unilateral conducts and agreements based on the Adalat case law. The Council's investigation of the insulin

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.